Breast Cancer
Hummingbird Bioscience, Merck to Study HMBD-002 With Keytruda in Various Solid Tumors
The firms plan to evaluate the anti-VISTA and anti-PD-1 therapies in a clinical trial for TNBC, NSCLC, and other cancers with high VISTA expression.
European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients
The approval makes Merck's PD-1 inhibitor available to European TNBC patients whose tumors express PD-L1 with a combined positive score of at least 10.
Cedilla Therapeutics Unveils Lead Drug Programs Targeting TEAD, CDK2
Cedilla plans to begin IND-enabling studies in 2022 of the TEAD and CDK2 inhibitors, which both have preclinical data showing activity in genetically aberrant cancers.
Menarini Group, Radius Health Advance Regulatory Plans for Elacestrant Breast Cancer Therapy
The drug improved progression-free survival over standard of care in ER-positive, HER2-negative advanced breast cancer patients with or without an ESR1 mutation.
Roche Q3 Pharmaceutical Revenues Grow 5 Percent Helped by Precision Cancer Drugs
HER2-targeted breast cancer drugs and the immunotherapy Tecentriq were among the top-selling therapies during the quarter.